Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Cowin Biotech CoSHSE:688426 +2.34%63 Current Ratio is 13.76 as of Mar. 2026, which is 1% above its 10-year median of 13.62. GuruFocus rates SHSE:688426 with a GF Score™ of 63/100 and a GF Value™ of ¥29.27 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Jiangsu Cowin Biotech Co ranks better than 84.61% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Jiangsu Cowin Biotech Co's current ratio for the quarter that ended in Mar. 2026 was 13.76.
Jiangsu Cowin Biotech Co has a current ratio of 13.76. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Jiangsu Cowin Biotech Co's Current Ratio or its related term are showing as below:
SHSE:688426'
s Current Ratio Range Over the Past 10 Years
Min: 2.1 Med: 13.62 Max: 25.6
Current: 13.76
During the past 8 years, Jiangsu Cowin Biotech Co's highest Current Ratio was 25.60. The lowest was 2.10. And the median was 13.62.
SHSE:688426's Current Ratio is ranked better than 84.61% of 1410
companies
in the Biotechnology industry
Industry Median: 3.88
vs SHSE:688426: 13.76
Jiangsu Cowin Biotech Co (SHSE:688426) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Jiangsu Cowin Biotech Co Current Ratio Related Terms
Jiangsu Cowin Biotech Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688426 vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Jiangsu Cowin Biotech Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Cowin Biotech Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Cowin Biotech Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Jiangsu Cowin Biotech Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Cowin Biotech Co (SHSE:688426) has a Current Ratio of 13.76 as of Mar. 2026. This is near median its historical median of 13.62. Over the past decade, Jiangsu Cowin Biotech Co's Current Ratio has ranged from 2.10 to 25.60. According to the industry distribution chart, Jiangsu Cowin Biotech Co ranks #217 out of 1410 companies in the Biotechnology industry, placing it in the top 15.4%.
Is Jiangsu Cowin Biotech Co's Current Ratio too high?
Jiangsu Cowin Biotech Co's current Current Ratio of 13.76 is near median its 10-year median of 13.62. Over the past 10 years, this metric has ranged from a low of 2.10 to a high of 25.60. The Biotechnology industry median Current Ratio is 3.88. Jiangsu Cowin Biotech Co's value of 13.76 is 254.6% above this industry median. Based on the distribution chart, Jiangsu Cowin Biotech Co ranks #217 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Cowin Biotech Co has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Cowin Biotech Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Cowin Biotech Co ranks #217 out of 1410 companies for Current Ratio. This places Jiangsu Cowin Biotech Co in the top 15% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. Jiangsu Cowin Biotech Co's value of 13.76 is 254.6% above this benchmark. Historically, Jiangsu Cowin Biotech Co's own Current Ratio has ranged from 2.10 to 25.60 over the past decade. While the company's 10-year median is 13.62 vs. the industry median of 3.88, Jiangsu Cowin Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Cowin Biotech Co's current Current Ratio of 13.76 is 254.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Cowin Biotech Co's current Current Ratio is 13.76, which is near median its own 10-year median of 13.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Cowin Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Cowin Biotech Co (SHSE:688426) is currently considered Possible Value Trap. The stock's GF Value™ is ¥29.27, compared to a current price of ¥15.30 — trading 47.7% below its estimated fair value. The current Current Ratio is 13.76, which is near median its 10-year median of 13.62 and 254.6% above the Biotechnology industry median of 3.88. Jiangsu Cowin Biotech Co's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Jiangsu Cowin Biotech Co (SHSE:688426), the current Current Ratio is 13.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Cowin Biotech Co (SHSE:688426) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Cowin Biotech Co stock appears to be undervalued.
The current stock price of ¥15.30 is trading 47.7% below its estimated GF Value™ of ¥29.27.
GuruFocus considers Jiangsu Cowin Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688426:
Current Ratio: 13.76 (near median its 10-year median of 13.62)
GF Value™: ¥29.27 vs. price of ¥15.30 (47.7% below fair value)
Industry Position: 254.6% above the Biotechnology median (#217 of 1410)
No single metric tells the full story. See the SHSE:688426 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Cowin Biotech Co Ltd is a national high-tech enterprise with independent intellectual property rights based in the field of life sciences. It provides innovative biological products and services to in vitro diagnostic users. The product line mainly includes molecular diagnostic raw materials enzymes, nucleic acid collection and protection agents, nucleic acid extraction kits, molecular diagnostic detection reagents and others.
63GF Score
Get the complete analysis for SHSE:688426
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688426 has been successfully added to your 
